Abstract
MIDD0301 is a novel new chemical entity (NCE) drug that targets GABAA receptors in the lung. This unique mechanism of drug action for asthma avoids common therapeutic targets, such as glucocorticoid and β-adrenergic receptors that are subject to tolerance and adverse effects. MIDD0301 is expected to have broader clinical utility compared to current inhaled and oral treatments due to alleviation of Th1 and Th2 mediated lung inflammation, in addition to the relief of airway hyperresponsiveness (AHR).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
